Keros Therapeutics (KROS) Stock Forecast, Price Target & Predictions
KROS Stock Forecast
Keros Therapeutics stock forecast is as follows: an average price target of $102.00 (represents a 498.59% upside from KROS’s last price of $17.04) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
KROS Price Target
The average price target for Keros Therapeutics (KROS) is $102.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $107.00 to $96.00. This represents a potential 498.59% upside from KROS's last price of $17.04.
KROS Analyst Ratings
According to 6 Wall Street analysts, Keros Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KROS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Keros Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Kelly Shi | Jefferies | $107.00 | $62.02 | 72.52% | 527.93% |
| Nov 05, 2024 | Srikripa Devarakonda | Truist Financial | $100.00 | $62.02 | 61.24% | 486.85% |
| Sep 23, 2024 | Vamil Divan | Guggenheim | $96.00 | $55.80 | 72.04% | 463.38% |
| Jun 18, 2024 | Joseph Catanzaro | Piper Sandler | $105.00 | $44.65 | 135.16% | 516.20% |
| Dec 13, 2022 | BTIG | $105.00 | $49.98 | 110.08% | 516.20% | |
| Jul 27, 2022 | Julian Harrison | BTIG | $80.00 | $31.79 | 151.65% | 369.48% |
| May 18, 2022 | Joseph Catanzaro | Piper Sandler | $120.00 | $39.92 | 200.60% | 604.23% |
The latest Keros Therapeutics stock forecast, released on Nov 05, 2024 by Kelly Shi from Jefferies, set a price target of $107.00, which represents a 72.52% increase from the stock price at the time of the forecast ($62.02), and a 527.93% increase from KROS last price ($17.04).
Keros Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $101.00 | $102.00 |
| Last Closing Price | $17.04 | $17.04 | $17.04 |
| Upside/Downside | -100.00% | 492.72% | 498.59% |
In the current month, the average price target of Keros Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Keros Therapeutics's last price of $17.04. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 16, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| Nov 05, 2024 | Jefferies | Buy | Initialise | |
| Oct 24, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
| Sep 23, 2024 | Guggenheim | Buy | Initialise | |
| Jun 24, 2024 | Oppenheimer | Outperform | Initialise | |
| Jun 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 13, 2022 | BTIG | Buy | Buy | Hold |
| Oct 10, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 27, 2022 | BTIG | Buy | Initialise |
Keros Therapeutics's last stock rating was published by Guggenheim on Dec 16, 2024. The company Downgrade its KROS rating from "Buy" to "Neutral".
Keros Therapeutics Financial Forecast
Keros Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $81.57K | $97.00K | $115.35K | $137.18K | $14.29K | $1.82M | $2.51M | $25.01M | $50.00K | $388.00K | $37.00K | $216.67K | $325.00K | $1.20M | $6.00M | $62.50K | $83.33K |
| High Forecast | $81.57K | $97.00K | $115.35K | $137.18K | $14.29K | $1.82M | $2.51M | $25.01M | $83.33K | $388.00K | $37.00K | $216.67K | $325.00K | $1.20M | $6.00M | $62.50K | $83.33K |
| Low Forecast | $81.57K | $97.00K | $115.35K | $137.18K | $14.29K | $1.82M | $2.51M | $25.01M | $16.67K | $388.00K | $37.00K | $216.67K | $325.00K | $1.20M | $6.00M | $62.50K | $83.33K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 6 | 3 | 2 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Keros Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KROS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Keros Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 6 | 3 | 2 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-37.31M | $-35.64M | $-29.72M | $-24.07M | $-11.96M | $-12.00M |
| Avg Forecast | $-16.31K | $-19.40K | $-23.07K | $-27.43K | $-2.86K | $-364.29K | $-502.50K | $-5.00M | $-10.00K | $-77.60K | $-7.25K | $-43.33K | $-65.00K | $-240.00K | $-19.87M | $-12.25K | $-110.99M |
| High Forecast | $-16.31K | $-19.40K | $-23.07K | $-27.43K | $-2.86K | $-364.29K | $-502.50K | $-5.00M | $-3.33K | $-77.60K | $-7.25K | $-43.33K | $-65.00K | $-240.00K | $-15.90M | $-12.25K | $-88.79M |
| Low Forecast | $-16.31K | $-19.40K | $-23.07K | $-27.43K | $-2.86K | $-364.29K | $-502.50K | $-5.00M | $-16.67K | $-77.60K | $-7.25K | $-43.33K | $-65.00K | $-240.00K | $-23.85M | $-12.25K | $-133.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 861.10% | 548.27% | 123.83% | 1.21% | 976.81% | 0.11% |
undefined analysts predict KROS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Keros Therapeutics's previous annual EBITDA (undefined) of $NaN.
Keros Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 6 | 3 | 2 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-37.51M | $-32.74M | $-29.72M | $-24.19M | $-12.04M | $-11.89M |
| Avg Forecast | $-35.29M | $-35.35M | $-35.40M | $-35.34M | $-47.93M | $-45.94M | $-46.39M | $-25.68M | $-49.25M | $-46.16M | $-45.43M | $-48.34M | $-40.54M | $-39.61M | $-19.97M | $-21.48M | $-126.41M |
| High Forecast | $-35.29M | $-35.35M | $-35.40M | $-35.34M | $-47.93M | $-45.94M | $-46.39M | $-22.89M | $-40.04M | $-46.16M | $-45.43M | $-48.34M | $-40.54M | $-39.61M | $-15.97M | $-21.48M | $-101.13M |
| Low Forecast | $-35.29M | $-35.35M | $-35.40M | $-35.34M | $-47.93M | $-45.94M | $-46.39M | $-28.10M | $-57.75M | $-46.16M | $-45.43M | $-48.34M | $-40.54M | $-39.61M | $-23.96M | $-21.48M | $-151.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 0.81% | 0.75% | 1.21% | 0.56% | 0.09% |
Keros Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KROS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Keros Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 6 | 3 | 2 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $8.80M | $7.78M | $7.09M | $6.05M | $3.55M | $1.98M |
| Avg Forecast | $3.82M | $4.54M | $5.40M | $6.42M | $668.78K | $85.27M | $117.62M | $1.17B | $2.34M | $18.16M | $1.73M | $10.14M | $15.21M | $56.18M | $4.99M | $2.93M | $3.90M |
| High Forecast | $3.82M | $4.54M | $5.40M | $6.42M | $668.78K | $85.27M | $117.62M | $1.17B | $3.90M | $18.16M | $1.73M | $10.14M | $15.21M | $56.18M | $5.99M | $2.93M | $3.90M |
| Low Forecast | $3.82M | $4.54M | $5.40M | $6.42M | $668.78K | $85.27M | $117.62M | $1.17B | $780.20K | $18.16M | $1.73M | $10.14M | $15.21M | $56.18M | $3.99M | $2.93M | $3.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.51% | 0.13% | 1.21% | 1.21% | 0.51% |
Keros Therapeutics's average Quarter SG&A projection for Jun 24 is $1.73M, based on 3 Wall Street analysts, with a range of $1.73M to $1.73M. The forecast indicates a -80.32% fall compared to KROS last annual SG&A of $8.80M (Jun 23).
Keros Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 6 | 3 | 2 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-1.27 | $-1.15 | $-1.09 | $-1.01 | $-0.60 | $-0.70 |
| Avg Forecast | $-0.98 | $-0.98 | $-0.98 | $-0.98 | $-1.33 | $-1.27 | $-1.28 | $-0.71 | $-1.36 | $-1.28 | $-1.26 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.59 | $-0.37 |
| High Forecast | $-0.98 | $-0.98 | $-0.98 | $-0.98 | $-1.33 | $-1.27 | $-1.28 | $-0.63 | $-1.11 | $-1.28 | $-1.26 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.59 | $-0.37 |
| Low Forecast | $-0.98 | $-0.98 | $-0.98 | $-0.98 | $-1.33 | $-1.27 | $-1.28 | $-0.78 | $-1.60 | $-1.28 | $-1.26 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.59 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.02% | 0.99% | 1.17% | 1.01% | 1.89% |
According to undefined Wall Street analysts, Keros Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KROS previous annual EPS of $NaN (undefined).
Keros Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| FENC | Fennec Pharmaceuticals | $6.07 | $15.75 | 159.47% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| IDYA | IDEAYA Biosciences | $26.33 | $53.33 | 102.54% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| HRMY | Harmony Biosciences | $33.63 | $48.00 | 42.73% | Buy |
| MGTX | MeiraGTx | $6.40 | $9.00 | 40.63% | Buy |
| JANX | Janux Therapeutics | $59.61 | $70.25 | 17.85% | Buy |